Geron (GERN) Stock Price, News & Analysis

Company Overview

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Key Stats

• Today's Range: $1.37 to $1.47
• 50-Day Range: $1.19 to $1.62
• 52-Week Range: $1.17 to $5.06
• Volume: 14.46 million shs
• Average Volume: 11.24 million shs
• Market Capitalization: $878.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.06
• Consensus Rating: Moderate Buy

Geron Stock Analysis - MarketRank™

Geron scored higher than 66% of companies evaluated by MarketBeat, and ranked 417th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Geron has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Geron has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Geron are expected to grow in the coming year, from ($0.25) to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Geron is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Geron is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Geron has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.06% of the float of Geron has been sold short.

Short Interest Ratio / Days to Cover

Geron has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Geron has recently increased by 1.01%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Geron does not currently pay a dividend.

Dividend Growth

Geron does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 1.3 / 5
• Environmental Score: -2.76

Percentage of Shares Shorted

11.06% of the float of Geron has been sold short.

Short Interest Ratio / Days to Cover

Geron has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Geron has recently increased by 1.01%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.27

News Sentiment

Geron has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Geron this week, compared to 12 articles on an average week.

Search Interest

Only 9 people have searched for GERN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Geron to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Geron insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.42% of the stock of Geron is held by insiders.

Percentage Held by Institutions

73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GERN Stock Analysis - Frequently Asked Questions

How have GERN shares performed this year?

Geron's stock was trading at $3.54 on January 1st, 2025. Since then, GERN stock has decreased by 59.7% and is now trading at $1.4250.
View the best growth stocks for 2025 here.

How were Geron's earnings last quarter?

Geron Corporation (NASDAQ:GERN) issued its quarterly earnings results on Wednesday, May, 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. The company's revenue for the quarter was up 12927.3% on a year-over-year basis.
Read the conference call transcript.

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Geron own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Geron investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Novavax (NVAX), Advanced Micro Devices (AMD), Intel (INTC) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GERN
• CIK: 886744
• Web: www.geron.com
• Phone: (650) 473-7700
• Fax: 650-473-7750
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.06
• High Stock Price Target: $9.00
• Low Stock Price Target: $1.50
• Potential Upside/Downside: +257.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$174.57 million
• Net Margins: -119.54%
• Pretax Margin: -119.54%
• Return on Equity: -47.86%
• Return on Assets: -26.78%

Debt

• Debt-to-Equity Ratio: 0.44
• Current Ratio: 7.87
• Quick Ratio: 6.97

Sales & Book Value

• Annual Sales: $76.99 million
• Price / Sales: 11.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: 3.08

Miscellaneous

• Outstanding Shares: 636,920,000
• Free Float: 589,659,000
• Market Cap: $901.24 million
• Optionable: Optionable
• Beta: 0.69